What is HC Wainwright’s Forecast for KALV FY2028 Earnings?

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) – Stock analysts at HC Wainwright decreased their FY2028 earnings estimates for shares of KalVista Pharmaceuticals in a research report issued to clients and investors on Friday, March 27th. HC Wainwright analyst A. Fein now forecasts that the specialty pharmaceutical company will earn $2.06 per share for the year, down from their previous estimate of $2.25. HC Wainwright has a “Buy” rating and a $37.00 price target on the stock. The consensus estimate for KalVista Pharmaceuticals’ current full-year earnings is ($3.56) per share.

Several other research firms have also recently commented on KALV. TD Cowen reaffirmed a “buy” rating on shares of KalVista Pharmaceuticals in a report on Wednesday, December 3rd. Weiss Ratings reissued a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research note on Thursday, January 22nd. Stifel Nicolaus upped their target price on KalVista Pharmaceuticals from $39.00 to $42.00 and gave the company a “buy” rating in a report on Thursday, March 26th. Needham & Company LLC raised their target price on KalVista Pharmaceuticals from $35.00 to $36.00 and gave the stock a “buy” rating in a research note on Wednesday, March 25th. Finally, Citizens Jmp reduced their price target on KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating on the stock in a report on Thursday, March 26th. Seven equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, KalVista Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $32.60.

KalVista Pharmaceuticals Trading Down 5.0%

Shares of KalVista Pharmaceuticals stock opened at $18.36 on Monday. The company has a debt-to-equity ratio of 8.18, a current ratio of 7.22 and a quick ratio of 7.21. The stock’s 50 day simple moving average is $16.12 and its 200-day simple moving average is $14.47. The stock has a market cap of $940.40 million, a P/E ratio of -4.65 and a beta of -0.35. KalVista Pharmaceuticals has a 1-year low of $9.23 and a 1-year high of $19.95.

Institutional Trading of KalVista Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of KALV. Vanguard Group Inc. raised its holdings in KalVista Pharmaceuticals by 3.7% in the 3rd quarter. Vanguard Group Inc. now owns 2,501,119 shares of the specialty pharmaceutical company’s stock valued at $30,464,000 after buying an additional 88,720 shares during the period. Tudor Investment Corp ET AL acquired a new position in KalVista Pharmaceuticals in the third quarter valued at about $24,360,000. State Street Corp boosted its stake in KalVista Pharmaceuticals by 21.3% during the fourth quarter. State Street Corp now owns 1,911,691 shares of the specialty pharmaceutical company’s stock worth $30,874,000 after buying an additional 336,195 shares during the period. Vestal Point Capital LP increased its position in shares of KalVista Pharmaceuticals by 152.0% during the fourth quarter. Vestal Point Capital LP now owns 1,890,000 shares of the specialty pharmaceutical company’s stock valued at $30,524,000 after acquiring an additional 1,140,000 shares during the last quarter. Finally, Parkman Healthcare Partners LLC increased its position in shares of KalVista Pharmaceuticals by 155.5% during the third quarter. Parkman Healthcare Partners LLC now owns 1,735,003 shares of the specialty pharmaceutical company’s stock valued at $21,132,000 after acquiring an additional 1,055,940 shares during the last quarter.

Insider Activity

In related news, insider Paul K. Audhya sold 5,354 shares of the company’s stock in a transaction that occurred on Monday, February 23rd. The stock was sold at an average price of $15.57, for a total value of $83,361.78. Following the transaction, the insider directly owned 138,983 shares in the company, valued at approximately $2,163,965.31. This represents a 3.71% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Benjamin L. Palleiko sold 6,693 shares of the stock in a transaction that occurred on Monday, March 9th. The stock was sold at an average price of $16.08, for a total value of $107,623.44. Following the completion of the transaction, the chief executive officer owned 451,815 shares of the company’s stock, valued at $7,265,185.20. The trade was a 1.46% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 248,009 shares of company stock worth $4,213,467. 4.30% of the stock is owned by company insiders.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.